One of my favorite topics…. Hospitals and health systems opening their own specialty pharmacies (HSSPs). We’ve written about this growing trend for several years, but
The FDA recently approved a new ORAL therapy, Rezurock (belumosudil) from Kadmon Pharmaceuticals, with an indication for adult and pediatric patients with chronic graft-versus-host disease
We’ve often written about the legal pitfalls that specialty pharmacies may encounter that end up costing them financially (HIPAA violations are top of mind). Today
Earlier this month the FDA approved a ‘new’ combination therapy, Darzalex Faspro (daratumumab and hyaluronidase-fihj), from Janssen Biotech. Darzalex was originally approved in 2015 with
It’s about time.It has been quite a while since we’ve heard about a specialty pharmacy acquisition. Over recent years there was a race to the
The public relations battle surrounding White Bagging is heating up.Who’s on each side?Depends on who you ask….!On one side, hospitals are claiming that their very
Here’s something that you don’t see every day….. We published the report below in November 2019 detailing the approval of Exservan, a drug first approved
We missed one….!The drug being recapped today was approved back in late February. We put it on the shelf till we could determine whether this
The FDA recently approved a specialty ORAL therapy, Truseltiq (infigratinib) from QED Therapeutics (one of several BridgeBio affiliates). Truseltiq was granted an indication for unresectable
Get yer Lumakras!Lumakras here! 90+% of FDA specialty approvals launched through limited distribution in 2011….. and that trend continues in 2021. As frequent readers know,
